Skip to main content
. 2015 Jan 21;97(3):215–217. doi: 10.1002/cpt.39

Figure 1.

Figure 1

A representation of the data requirements for the development of a standalone biologic [351(a)] as compared to those expected for a biosimilar/interchangeable biologic [351(k)]. The concept of biosimilarity is fundamentally different from that applied to an originator biologic where safety, purity, and potency must be established a priori.